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Review
mRNA cap regulation in mammalian cell function and fate☆
Alison Galloway, Victoria H. Cowling⁎
Centre for Gene Regulation and Expression, School of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK
A B S T R A C T
In this review we explore the regulation of mRNA cap formation and its impact on mammalian cells. The mRNA cap is a highly methylated modification of the 5′ end
of RNA pol II-transcribed RNA. It protects RNA from degradation, recruits complexes involved in RNA processing, export and translation initiation, and marks
cellular mRNA as “self” to avoid recognition by the innate immune system. The mRNA cap can be viewed as a unique mark which selects RNA pol II transcripts for
specific processing and translation. Over recent years, examples of regulation of mRNA cap formation have emerged, induced by oncogenes, developmental pathways
and during the cell cycle. These signalling pathways regulate the rate and extent of mRNA cap formation, resulting in changes in gene expression, cell physiology and
cell function.
1. The mRNA cap
RNA pol II-transcribed RNA typically constitutes less than 5% of the
total RNA in mammalian cells. RNA pol II-transcribed RNA includes
pre-mRNA (messenger RNA), pre-miRNA (micro RNA), pre-lncRNA
(long non-coding RNA), snoRNAs (small nucleolar RNAs), and snRNA
(small nuclear RNA). The majority of cellular RNA is rRNA (ribosomal
RNA) and tRNA (transfer RNA) which is transcribed by RNA pol I and
III. RNA pol II products, therefore, represent a functionally distinct
group that must be processed, transported and, in the case of mRNA,
translated, separately from other RNA species: this requires a mark of
their identity. RNA pol II products are uniquely marked during tran-
scription by the addition of a methylated guanosine cap structure to the
5′ terminus. The mRNA cap blocks 5′-3′ exonuclease-mediated de-
gradation and recruits specific RNA processing, export and translation
factors [1,2]. Removal of the cap (decapping) initiates degradation of
mRNA [3]. Thus the cap is mechanistically involved in every stage of
the mRNA lifecycle. Other RNA pol II-transcribed RNA species are also
capped, but the cap structure and function varies. For example, pre-
miRNA loses its cap during maturation, and snRNA and snoRNA caps
can be further modified to a tri-methylguanosine (TMG) cap [4]. In this
review we will focus on the regulation and role of the mRNA cap.
2. mRNA cap modifications
In mammals, the predominant cap structure is 7-methylguanosine
linked via a 5′ to 5′ triphosphate bridge to the first transcribed nu-
cleotide, which is methylated on the ribose O-2 position (denoted
m7G(5′)ppp(5′)Xm, X is the first transcribed nucleotide) [2,5] Fig. 1.
m7G(5′)ppp(5′)Xm was initially presumed to be present on all mRNA,
however, due to advances in biochemistry, organ-specific and cell-
specific levels of N-7 cap guanosine methylation and O-2 first nucleo-
tide ribose methylation have been observed [6–10]. This suggests dif-
ferential regulation of mRNA cap formation in different cell lineages
and/or in response to specific signalling pathways. In addition, 2nd
transcribed nucleotide ribose O-2 methylation and first nucleotide
Adenosine N-6 methylation are also readily observed [11,12]. First
nucleotide Adenosine N-6 methylation is an abundant modification,
with m7G(5′)ppp(5′)m6Am contributing 20–30% of m7G(5′)ppp(5′)Xm
mRNA caps in HeLa cells [13]. Since modifications such as Adenosine
N-6 methylation are nucleotide-specific, and since cap binding proteins
may have nucleotide preferences, the transcription start site impacts on
the cap structure by determining the first transcribed nucleotide [14].
The range of modifications which are detected on internal positions of
RNAs may also be present on the cap guanosine and cap proximal nu-
cleotides. However, the enzymes that have been demonstrated to me-
thylate the cap and adjacent nucleotides are specific for the cap struc-
ture and it is unlikely that enzymes which modify internal residues will
also modify the cap [1,4].
Recently, a different type of cap structure, the nicotinamide adenine
dinucleotide (NAD) cap, which was originally identified in bacteria and
yeast, was identified in mammalian cells [8,15]. NAD caps targets
transcripts for degradation [8]. Although the proportion of mRNA
carrying a NAD cap is low in HEK293T cells, it may well be elevated
and/or regulated in other cell lines or primary tissues [16]. The level of
NAD capping is determined at least in part by the cellular concentration
of NAD. The challenge going forward will be to detect lower abundance
modifications and determine their functional significance. Determining
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the function of cap modifications in cells is greatly facilitated by
identifying the enzymes which catalyse synthesis or removal.
3. Function of the mRNA cap
The known functions of the mRNA cap are mediated by its inter-
actions with binding proteins and complexes (Fig. 2). A cap modifica-
tion may influence the affinity of the cap to its various co-factors
[17–19].
3.1. RNA processing and translation: CBC and eIF4F
CBC (cap binding complex) and eIF4F (eukaryotic initiation factor
4F) are the major mRNA cap binding complexes in mammalian cell
lines. The predominantly nuclear CBC consists of a cap binding protein,
NCBP2 (nuclear cap binding complex 2/CBP20) and its interacting
partner, NCBP1 (nuclear cap binding complex 1/CBP80). CBC binds to
the cap and recruits mechanistic proteins to the pre-mRNA, promoting
splicing of the first intron, 3′-end processing, nuclear export and in-
itiation of the pioneer round of translation [1,20]. For some mRNA,
particularly histones, CBC can also be involved in subsequent rounds of
translation [21]. For the majority of mRNA in the cytoplasm, the mRNA
cap binds to the cap binding complex, eIF4F, which promotes transla-
tion initiation [4]. The eIF4F protein complex consists of a cap binding
protein, eIF4E, a scaffold protein eIF4G and a helicase eIF4A (or their
isoforms). When bound to the cap, eIF4F recruits the initiation factor
eIF3, which in turn recruits the initiator tRNA and 40S ribosome sub-
unit. eIF4E also has nuclear functions including in RNA export of spe-
cific transcripts [22]. The cap binding component of eIF4F, eIF4E, is
regulated through the mTOR (mammalian target of rapamycin) and
MNK1/2 (MAP Kinase Interacting Serine/Threonine Kinase) signalling
pathways, coupling cap-dependent translation initiation to nutrient,
oxygen and growth factor availability [23]. In contrast to eIF4F-medi-
ated translation, CBC-mediated translation is resistant to mTOR-de-
pendent inhibition [21,24].
Both CBC and eIF4F have a strong preference for the cap guanosine
to be methylated. eIF4E binds to m7G(5′)ppp(5′)G with 1000-fold
greater affinity than G(5′)ppp(5′)G, and NCBP2 has more than 150-fold
greater affinity for m7G(5′)ppp(5′)G than G(5′)ppp(5′)G [25,26]. Both
CBC and eIF4F also have increased affinity for the cap when the first
transcribed nucleotide is a purine and a moderate increases in affinity
for cap analogues when the first transcribed nucleotide is O-2
methylated. Consistent with this, first transcribed nucleotide O-2 me-
thylation has a role in translation initiation [27–30].
3.2. RNA processing and translation: alternative cap binding complexes
Homologues and alternatives of CBC and eIF4F introduce diversity
into cap-dependent mRNA regulation. The most abundant CBC is
NCBP1-NCBP2, however, NCBP3 is a m7G cap-binding protein which
forms an alternative cap binding complex with NCBP1 [31]. In cells
growing under steady-state conditions the NCBP1-NCBP2 and NCBP1-
NCBP3 complexes functionally overlap, however, NCBP3 has a critical
role in clearing viral infections. NCBP3 bears no homology to NCBP2
and in a separate study it was shown to have low affinity for m7GTP,
leading the authors to conclude that it does not have a major role in cap
binding [32]. However, NCBP3 may have higher affinity for complete
cap structures, in which the first few transcribed nucleotides may be
important.
eIF4E has two homologues eIF4E2 and eIF4E3 [33]. Although ori-
ginally described as suppressive competitors of eIF4E with lower affi-
nity for the cap structure, both have now been shown to regulate
translation under particular conditions [34]. eIF4E2 has been shown to
mediate translation in hypoxic conditions when eIF4E is inhibited.
Hypoxia stimulates formation of a complex containing eIF4E2, HIF-2α
(hypoxia inducible factor 2α), and RBM4 (RNA binding motif protein
4), which binds to RNAs containing RNA hypoxia response elements
(rHRE) and recruits them to the ribosome. Certain mRNA bearing rHRE
(hypoxia response elements) have enhanced dependency on eIF4E2 for
translation.
eIF4E3 competes with eIF4E for cap binding when it is over-
expressed and has been shown to decrease expression of oncogenic
proteins and impair cell transformation [35]. When cells are treated
with an MNK inhibitor, eIF4E3 expression is increased and mediates
translation initiation [36]. The eIF4E3-dependent translatome overlaps
with that of eIF4E, but certain mRNAs, including those involved in the
NFκB pathway, are preferentially translated by eIF4E. eIF4E2 binds to
the mRNA cap through a similar mechanism to eIF4E whereas eIF4E3
has an atypical binding mechanism [35,37]. Although eIF4E2 and
eIF4E3 bind to m7G, the cap binding specificities of these alternative
subunits have not been extensively investigated.
eIF3D, a subunit of the eIF3 complex, has cap binding activity which
allows translation of particular mRNAs, including cJUN mRNA, in an
eIF4E-independent mechanism [38]. eIF3D-mRNA binding is
Fig. 1. The mRNA cap.
A predominant cap structure in mammalian cells is depicted. 7-Methylguanosine is linked to the first transcribed nucleotide via a 5′ to 5′ triphosphate bridge. The first
transcribed nucleotide is methylated on the O-2 position of the ribose. Other methylations are also observed including first transcribed nucleotide adenosine
methylation on position 6 and second transcribed nucleotide ribose O-2 methylation.
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competitively inhibited by m7GDP and not GDP indicating a specificity
towards N-7 methylated cap guanosine.
In addition to the two major cap binding complexes, CBC and eIF4F,
newly identified cap binding proteins are expanding our understanding
of cap function. LARP1 binds to the cap and the 5′ terminal oligo
pyrimidine (TOP) motif present on transcripts encoding ribosomal
proteins and selected translation factors [39]. By binding to the cap
LARP1 stabilises transcripts [40], but blocks eIF4E binding and trans-
lation [41]. mTOR-dependent phosphorylation of LARP1 releases the
mRNA cap allowing translation to occur, linking the production of ri-
bosomes to cell growth [41]. Although LARP1 binds to a TOP motif
with a m7G(5′)ppp(5′)C cap and not a decapped equivalent, it is not
clear whether methylation of the cap structure contributes to binding.
For other cap binding proteins and complexes, the biological con-
sequences of their cap binding activity is less well understood; Pumilio
2 has been shown to be capable of competing with eIF4E to inhibit
translation [42], and the exon-junction complex core heterodimer Y14/
Magoh binds to the mRNA cap and inhibits the decapping activity of
DCP2 [43]. It is not yet known whether these proteins have specificity
for particular RNAs.
3.3. Decapping and RNA decay
A major mechanism through which cap binding proteins enhance
mRNA stability is by blocking the access of RNA decapping and decay
enzymes [3]. The majority of decapping enzymes hydrolyse the tri-
phosphate bridge connecting the inverted guanosine to the first tran-
scribed nucleotide, removing either m7GMP or m7GDP from the 5′ end
of the mRNA. DXO (Decapping Exoribonuclease) can also cleave be-
tween the first and second transcribed nucleotide [44]. Removal of the
cap allows 5′-3′ decay to proceed.
There are several mammalian decapping enzymes which have dif-
ferent target preferences [3]. For example, the DCP2 is recruited to
specific mRNA by RNA binding proteins and miRNAs (micro RNAs) that
bind to cis acting elements on the transcript, whereas NUDT16 is more
ubiquitous [3,45]. NUDT3 influences cell migration by through selec-
tive decapping of integrin β6 and lipocalin-2 mRNAs [46]. Several
decapping enzymes also appear to have RNA binding activity which
may aid target selection. For some decapping enzymes, variation in the
cap structure itself influences decapping activity directly. Recently first
nucleotide O-2 methylation was shown to prevent mRNA decapping by
the enzyme DXO which has reduced affinity for caps with methylated
first transcribed nucleotides [47]. DCP2 decapping activity is not
Fig. 2. mRNA cap function.
mRNA cap formation initiates during transcription. The mRNA cap protects pre-mRNA from decay during transcription. CBC (cap binding complex) binds to the
mRNA cap and recruits proteins which mediate splicing, polyadenylation and export into the cytoplasm. eIF4F (eukaryotic initiation factor 4F) binds to the cap and
recruits the 40S ribosomal subunit, initiating translation. The mature mRNA cap inhibits the action of 5′-3′ exonucleases until it is removed by the decapping
enzymes. Antiviral responses can be induced by incomplete caps, particularly those with tri-phosphate ends or lacking O-2 methylation on the first and second
transcribed nucleotides.
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affected by first transcribed nucleotide O-2 methylation, but is inhibited
by N6 methylation of adenine in the first position. Thus, transcripts
beginning with m6Am are resistant to miRNA mediated degradation
[48]. N6A methylation is reversed by FTO (fat mass and obesity-asso-
ciated protein), thereby influencing decapping and mRNA stability
[48]. Humans with FTO loss-of-function mutations exhibit growth re-
tardation and other issues, which may in part be due to aberrant cap
metabolism and subsequent gene dysregulation [49].
Decapping prepares mRNA for 5′-3′ decay, however, the polyA tail
is also susceptible to 3′-5′ degradation. PolyA tail shortening reduces
the translation efficiency of mRNA and enhances decapping.
Interestingly PARN (Poly-A specific ribonuclease), the enzyme re-
sponsible for polyA tail shortening is also a cap binding protein and
PARN-mediated degradation of RNA ending in triphosphate is in-
efficient indicating that the cap marks mRNA for this specific de-
gradation pathway [50].
3.4. Cap binding proteins involved in the antiviral response
The innate immune system is able to recognise non-self RNAs
through pattern recognition receptors (PRRs) [51,52]. One such PRR,
RIG-1 (retinoic acid inducible 1; DDX58, Dead Box Helicase 58) is able
to recognise double stranded RNA with either cap structures lacking
first transcribed nucleotide O-2 methylation, or with 5′ di or tri-phos-
phate structures [53,54]. O-2 methylation of the first transcribed nu-
cleotide is most effective at blocking RIG-1 binding to m7G capped
RNA, but second transcribed nucleotide O-2 methylation also has an
impact. RIG-1 binding to non-self RNA stimulates an Interferon β re-
sponse and increased expression of IFIT (IFN-induced protein with
tetratricopeptide repeats) proteins, some of which mediate the innate
immune response. Inhibition of O-2 methylation on endogenous mRNA
can also induce these responses, which could mediate a stress response
in certain cellular contexts [53]. IFIT proteins bind to single stranded
RNA with aberrant cap structures and repress translation. Their binding
specificities vary; IFIT1 binds to capped RNA with m7G(5′)ppp(5′)G,
G(5′)ppp(5′)G or A(5′)ppp(5′)G caps with little selection, but cannot
bind to RNA with first or second transcribed nucleotide ribose O2
methylated [55]. IFIT5 binds only to uncapped triphosphate ended
RNAs [56]. IFIT proteins have a role in inhibiting translation of viral
RNA, but it is not known whether they have a physiological role in
repressing cellular RNAs with incomplete cap structures.
4. mRNA capping enzymes
mRNA cap formation is catalysed by a series of enzymes [1,4]. The
biochemical mechanism of mRNA cap formation is likely to be the same
in all species in which it is found, Fig. 3. However the enzymes involved
have diverged in different species [1,57]. Additionally, the mRNA
capping enzymes have evolved to receive regulatory signals which can
result in changes in their expression, localisation and activity. In par-
ticular, in vertebrates there are additional mRNA capping enzymes,
regulatory domains and subunits that are absent in yeast, through
which signalling pathways can regulate mRNA cap formation and
therefore gene expression. In this review, we will discuss mechanisms
by which the mammalian capping enzymes are regulated and the re-
sultant impact on gene regulation, cell function and cell fate.
4.1. RNGTT
The first transcribed nucleotide of RNA pol II products retains the 5′
triphosphate, ppp(5′)X, to which the 7-methylguanosine cap is added,
Fig. 3. Initially RNGTT (RNA guanylyltransferase and 5′ phosphatase;
CE, Capping Enzyme), catalyses guanosine cap addition [58,59]. In
vertebrates, RNGTT has two catalytic sites, a triphosphatase and gua-
nylyltransferase. The triphosphatase removes the terminal phosphate to
create diphosphate-terminated RNA, pp(5′)X. Subsequently the
guanylyltransferase hydrolyses GTP (guanosine triphosphate) and
forms a covalent linkage with the product, GMP, which is transferred to
pp(5′)X to create the first cap structure G(5′)ppp(5′)X. RNGTT is re-
cruited to Serine-5 phosphorylated C-terminal domain (CTD) of RNA
pol II at the initiation of transcription and the enzyme is positioned to
act on the nascent transcript immediately as it emerges from the
polymerase [60]. Interaction with Ser-5 phosphorylated CTD also in-
creases the activity of the guanylyltransferase [61]. Although guany-
lylation of the nascent transcript is reversible in vitro, in cells the reverse
reaction is likely to be limited due to the interaction of RNGTT with Ser-
5 phosphorylated CTD being restricted to the initial stages of tran-
scription [62]. In other eukaryotes the triphosphatase and guanylyl-
transferase are distinct enzymes; having both activities on a single
polypeptide allows efficient coupling of the reactions to create the
guanosine cap.
4.2. RNMT
Addition of the inverted guanosine group to nascent transcripts
creates the substrate cap for a series of methyltransferases [63]. RNMT
(RNA guanine-7 methyltransferase), methylates the N-7 position of the
guanosine cap [64,65]. The catalytic region of RNA guanine-7 me-
thyltransferases is well conserved in different species, however the non-
catalytic, N-terminal domain is divergent even between mammalian
species [66]. A significant concentration of post-translational mod-
ifications (including acetylation, methylation, phosphorylation) are
found on the RNMT N-terminal domain [67]. This domain is a substrate
for modification by signalling pathways which regulate RNMT activity
(discussed later) [68]. In human RNMT, the N-terminal domain re-
strains methyltransferase activity; its removal increases catalytic ac-
tivity 2-fold [69]. Since the structure of this domain has not been de-
termined, the mechanism by which it influences catalytic activity is
unclear. The N-terminal domain is also required for efficient recruit-
ment to chromatin [69]. RNMT is recruited to transcription initiation
sites in a phospho-RNA pol II CTD-dependent manner, although direct
interaction is unlikely.
4.3. RAM
In vertebrates, the cap guanosine N-7 methyltransferase, RNMT, has
an activating subunit, RAM (RNMT-activating miniprotein) [70]. RAM
stabilises the structure and positioning of the RNMT lobe and adjacent
helix hinge, resulting in optimal positioning of helix A which contacts
substrates in the active site [71]. RAM increases the binding of the
methyl donor, s-adenosyl methionine (SAM), to the RNMT active site
and may be particularly important for cap guanosine methylation under
conditions of limiting SAM. RAM also has an RNA binding domain,
which is not required for methyltransferase activity in vitro, whereas in
cells it may be required to increase the efficiency of RNA substrate
recruitment, or enhance the recruitment of specific substrates [72]. To
date a consensus sequence for RAM binding has not been reported.
Although mRNA cap methylation occurs during the early stages of
transcription in the nucleus, RNGTT and RNMT-RAM are also present in
the cytoplasm where they can catalyse mRNA cap guanosine addition
and methylation [73,74]. This mechanism may cap mRNA that escaped
cap formation during transcription or decapped mRNA. In addition to
its role in mRNA cap methylation, RNMT-RAM promotes transcription,
independently of its role in mRNA cap methylation [75]. Suppression of
RNMT-RAM expression results in over 80% loss in RNA pol II peaks on
chromatin and a 2-fold drop in global transcription. RNMT-RAM in-
teracts with nascent transcripts along their entire length and with
transcription-associated factors including RNA pol II subunits, SPT4,
SPT6 and PAFc. The emerging model is that interactions between
RNMT-RAM, RNA and RNA pol II factors stimulate transcription [75].
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4.4. CMTR1
In mammals, the ribose of the first and second transcribed nucleo-
tides is methylated on the O-2 position by CMTR1 (Cap
Methyltransferase 1) and CMTR2 (Cap methyltransferase 2), respec-
tively [11,76]. CMTR1 is a multi-domain protein consisting of a G-patch
domain, a RrmJ/FtsJ methyltransferase domain, a non-functional cap
guanylyltransferase-like domain and a WW domain [27,77]. Deletion of
the domains C-terminal to the methyltransferase, the guanylyl-
transferase-like and WW domains, reduces the activity of CMTR1 in
vitro and therefore these domains may contribute to substrate recruit-
ment and/or structural configuration. These CMTR1 domains may
provide a platform by which co-factors and post-translational mod-
ifications can mediate regulation of ribose O-2 methylation. The
CMTR1 WW domain interacts with Ser-5 phosphorylated C-terminal
domain (CTD) of RNA Pol II [77,78]. Since CMTR1 methylates G(5′)ppp
(5′)X and m7G(5′)ppp(5′)X equivalently, it is possible that CMTR1 acts
prior to RNMT [76,79].
4.5. CMTR2
CMTR2, the second transcribed nucleotide ribose O-2 methyl-
transferase, also has several functional domains [11,79]. The N-term-
inal half of CMTR2 contains the methyltransferase domain. The C-ter-
minus contains a methyltransferase-like domain, which does not have a
competent active site but is required for CMTR2 methyltransferase ac-
tivity. CMTR2-dependent methylation does not require a N-7 methy-
lated cap guanosine or a first nucleotide O-2 methylated ribose, how-
ever these structures increase the efficiency of 2nd nucleotide ribose O-
2 methylation [11]. CMTR2 is found in both the nucleus and cytoplasm
of MCF7 cells [11].
4.6. Other capping enzymes
Enzymes involved in other cap methylations have not been identi-
fied to date [48]. As previously discussed, the enzymes which catalyse
cap modifications are unlikely to be the same as the enzymes which
catalyse internal RNA modifications since the cap structure fits into
mRNA cap methyltransferase active sites [71,79]. The first transcribed
nucleotide N6A methyltransferase is of particular interest since the
m7G(5′)ppp(5′)m6Am cap is highly abundant in HeLa cells [13].
5. Major cellular mechanisms of mRNA cap regulation in
mammals
The mRNA capping enzymes, similar to most enzymes can be
regulated at several levels; expression, activity, recruitment to substrate
(including subcellular localisation), and specificity for substrate. The
majority of the signalling pathways which influence the capping en-
zymes deposit regulatory post-translational modifications on the en-
zymes or regulate the action or expression of co-factors. Since me-
thyltransferases can be inhibited by their bi-product, s-adenosyl
homocysteine (SAH), mRNA cap methylation can also be regulated by
factors that regulate the enzyme SAHH (s-adenosyl homocysteine hy-
drolase) which hydrolyses SAH [80].
5.1. Serine-5 phosphorylated RNA pol II CTD
mRNA cap formation initiates during the early stages of transcrip-
tion, with RNGTT recruitment to the RNA pol II large subunit, Fig. 4
[60,81]. As described earlier, RNGTT is recruited to Ser-5 phosphory-
lated RNA Pol II CTD, and the guanylyltransferase activity is stimulated
by this interaction [61]. CMTR1 is also recruited to Ser-5 phospho-CTD
Fig. 3. mRNA cap synthesis.
The major capping reactions in mammalian cells are depicted.
Other methylation events on first and second transcribed
nucleotide are observed. Enzyme symbol, name and function
in blue. SAM is s-adenosyl methionine. SAH is S-adenosyl
homocysteine. RNMT, CMTR1, CMTR2 can all act on G(5′)
ppp(5′)XpX; i.e. no prior methylation of the cap is required.
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and RNMT is recruited to RNA pol II, probably indirectly, in a phospho-
CTD-dependent manner [69,77,78]. Currently, there is no evidence that
RNMT and CMTR1 are activated by interaction with the RNA pol II
CTD. Since Ser-5 phosphorylation of the RNA pol II CTD is a basic re-
quirement of transcription, this recruitment and activation of the cap-
ping enzymes can be perceived as a basal mechanism of gene expres-
sion. However, many signalling pathways can impact on RNA pol II
CTD phosphorylation, including transcription factors which increase
CTD phosphorylation at specific genes [82]. c-Myc and E2F1 have been
demonstrated to increase RNA pol II CTD phosphorylation and the
proportion of their target transcripts with an m7G(5′)ppp(5′)X cap
[7,83–85]. Furthermore, many transcription factors influence CTD
phosphorylation, and they too may increase gene-specific cap forma-
tion.
5.2. Cell cycle
The N-terminus of RNMT is a non-catalytic regulatory domain
which receives a heavy concentration of post-translational modification
[67,69]. RNMT is phosphorylated on Thr-77 during late G2 phase,
throughout mitosis and into early G1-phase [68], Fig. 4. Thr-77 phos-
phorylation increases RNMT activity, therefore providing a boost of cap
guanosine N-7 methylation during early G1 phase, when the majority of
transcription is occurring. In HeLa cells, CDK1-cyclin B is the pre-
dominant RNMT Thr-77 kinase. However the amino acid sequence
surrounding Thr-77, Gly-Lys-Asp-Thr-Pro-Ser-Lys, indicates that many
other proline-directed kinases may phosphorylate this site in other cells
and/or in other cellular contexts.
5.3. Embryonic stem cell differentiation
The RNMT co-factor RAM activates RNMT methyltransferase ac-
tivity and has an RNA binding domain which may enhance cap gua-
nosine N-7 methylation in vivo [70,72]. When it was discovered, RAM
was presumed to be a constitutive RNMT co-factor. In the cancer cell
lines in which they were investigated, RNMT and RAM were isolated as
heterodimers; monomers were unstable and undetectable. However
when investigated in primary cells and in vivo, RNMT and RAM were
found to be expressed differentially in different tissues, suggesting that
these proteins can be stabilised by other co-factors or post-translational
modifications in different cell types [86].
In embryonic stem (ES) cells, expression of RNMT and RAM is re-
latively high. However, the co-dependency of RNMT and RAM ex-
pression is minimal in ES cells and therefore their cellular concentra-
tions can be independently modified. RAM expression is controlled by
ERK1/2-dependent Ser-36 phosphorylation which triggers ubiquitin-
dependent degradation. When cells are pluripotent, ERK1/2 activity is
suppressed and RAM expression is maintained. During neural differ-
entiation, ERK1/2 activity is upregulated resulting in RAM Ser-36
phosphorylation and ubiquitin-dependent degradation, whereas RNMT
expression is largely maintained [86]. This regulation of RAM has both
global and gene-specific impacts. In ES cells, RAM is required for the
efficient translation of all mRNA, but is also required for the mRNA
expression of pluripotency-associated genes. Repression of RAM during
neural differentiation is required for repression of pluripotency-asso-
ciated mRNAs and the emergence of neural markers. As with RNMT
Thr-77, RAM Ser-36 lies within a motif, Pro-Pro-Glu-Ser-Pro-Pro, which
indicates that it could be phosphorylated by other kinases in other cells
or under other conditions. RAM expression is also repressed relative to
RNMT in many other organs, indicating that its repression may be re-
quired for the differentiation of many other lineages. Of note RAM is
upregulated with respect to RNMT in cardiac tissue, suggesting that it
can have a role independent of cap guanosine methylation.
5.4. DHX15
The predominant CMTR1-interacting protein is DHX15, an RNA
helicase with roles in RNA processing and ribosome biogenesis [78,87].
Approximately half of CMTR1 in HeLa cells is bound to DHX15. The
DHX15 OB-fold binds to the CMTR1 G-patch domain, an interaction
which represses methyltransferase activity by approximately 50%.
Furthermore, when bound to DHX15, CMTR1 does not interact with
RNA pol II, further restricting its activity. These mechanisms may
constrain O-2 methylation to a predominantly co-transcriptional event.
Conversely, CMTR1 activates DHX15 helicase activity which has a wide
range of roles in RNA processing [87].
5.5. Innate immunity
CMTR1 was first characterised as KIA0082/ISG95, a protein im-
plicated in the response to interferon treatment and viral infection
[88–91]. CMTR1-dependent first transcribed nucleotide ribose O-2
Fig. 4. Regulation of mRNA cap synthesis.
Phospho-RNA pol II CTD (C-terminal domain) recruits RNGTT
and activates guanylyltransferase activity, and recruits RNMT
and CMTR1. c-Myc, E2F-1 and other transcription factors
promote RNA pol II phosphorylation. In embryonic stern cells,
the pluripotency-associated gene network represses ERK 1/2
activity; during differentiation loss of pluripotency is asso-
ciated with increased ERK1/2 activity which phosphorylates
RAM-S36 resulting in ubiquitin-dependent degradation. T cell
activation resulting in upregulation of SAHH expression
which hydrolyses SAH, the inhibitory product of methylation
reactions. CDK1-cyclin B1 phosphorylates RNMT T77 which
increases methyltransferase activity. During the innate im-
mune response CMTR1 is upregulated.
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methylation is important for the identification of mRNA as “self”, pre-
venting its recognition by innate immune response proteins [53,54,91].
CMTR1 expression is increased following interferon treatment which is
likely to protect cellular RNAs. Upregulation of CMTR1 may also impact
cellular mRNA translation during the interferon response.
5.6. Cancer
Some of the factors which stimulate mRNA cap formation are ele-
vated in certain tumour types, including expression of c-Myc, E2F1 and
CDK1, and RNA pol II phosphorylation. Overexpression of RNMT en-
hances cellular transformation alone as well as in combination with
MYC and RAS, and inhibition of RNGTT specifically targets cells with
high levels of c-Myc expression, raising the possibility of the mRNA
capping enzymes as therapeutic targets [85,92]. Furthermore, the ele-
vated rates of transcription observed in cells expressing oncogenes may
render them particularly dependent on high rates of mRNA cap for-
mation. Since methyltransferases are inhibited by their bi-product,
SAH, mRNA cap methylation can be regulated by changes in expression
of SAHH (S-adenosyl homocysteine hydrolase), the enzyme which hy-
drolyses SAH [80]. SAHH is a c-Myc-induced gene and has been de-
monstrated to be required for mRNA cap formation, protein synthesis
and cell proliferation following c-Myc deregulation [80]. SAHH is also
upregulated following T cell activation which may facilitate the in-
creased requirement for mRNA cap methylation and other methylation
reactions during increased gene expression [80]. The mRNA cap me-
thyltransferases may be more appropriate than RNGTT as therapeutic
targets since their active-site inhibitors tend to be of low polarity and
able to cross the plasma membrane. In the case of RNMT, targeting
RAM may retain basal cap methyltransferase activity, reducing toxicity
[70,71]. Furthermore, since cancer cell lines have enhanced de-
pendency on RAM compared to non-transformed cells, targeting RAM
may enhance selectivity for transformed cells [70,86].
Cap binding proteins including LARP1 and eIF4E also have onco-
genic activities, probably via the control of key target genes [93,94].
The mTOR and MNK pathways that regulate eIF4E-dependent transla-
tion are currently being targeted individually and together to antag-
onise mRNA translation in cancer cells [95]. Inhibitors which directly
disrupt the interaction between eIF4E and eIF4G have also been de-
veloped [96]. Presumably, inhibitors of the capping enzymes will have
overlapping sets of target transcripts with eIF4E inhibitors. There is also
evidence that certain decapping enzymes may be useful therapeutic
targets [97].
The viral dsRNA sensor RIG-1 is associated with tumour suppressive
functions which are being investigated as targets in cancer im-
munotherapy [98–100]. RNAs with 5′ tri-phosphate activate RIG-1,
including bifunctional 5′ tri-phosphate siRNAs that silence oncogenic
mRNAs [101–106]. These RNAs have anti-tumour effects in a variety of
cancer cell lines and mouse tumour engraftment models. Mechanisms
for RIG-1 agonist-mediated tumour suppression included the induction
of apoptosis through a variety of effectors and the activation of immune
responses from dendritic cells and CD8 T lymphocytes. Since knock-
down of CMTR1 has proven effective in stimulating RIG-1, presumably
by increasing endogenous mRNAs lacking first transcribed nucleotide
O-2 methylation, CMTR1 inhibitors may also have anti-tumour activ-
ities [53]. RIG-1 also has ligand-independent roles, notably in re-
straining proliferation during granulopoiesis [107] and leukaemias
[108,109], and in mediating the effects of IFNα (interferon alpha)
[108]. The potential contribution of self-RNAs to regulate RIG-1 ac-
tivity in these contexts has not been thoroughly explored.
6. Challenges of mRNA cap research
Early during mRNA cap discovery, three structures were identified
and defined, Cap 0 (G(5′)ppp(5′)X), cap 1 (m7G(5′)ppp(5′)Xm), and cap
2 m7G(5′)ppp(5′)XmXm (both first and second transcribed nucleotides
methylated on the ribose O-2 position) [99]. We now recognise the
existence of NAD caps and additional modifications of the first tran-
scribed nucleotides are emerging. Furthermore we identify G(5′)ppp(5′)
X, G(5′)ppp(5′)Xm, G(5′) and m7G(5′)ppp(5′)X in significant quantities
in liver extracts (unpublished data). Following the identification of
novel, low abundance cap modifications, the challenge is it to de-
termine their function. Some mRNA cap-dependent processes (e.g.
translation initiation) can be readily reconstituted in vitro. However
other mRNA cap-dependent processes (e.g. splicing, export) are most
reliably studied in intact cells because they require intact cellular
components and/or are most efficient when coupled to other cellular
processes. Therefore the investigation of the function of novel mod-
ifications is enhanced by the identification of the enzymes involved and
their deletion/modification in cells. It is worth noting that not all
modifications of the first few transcribed nucleotides will have a
function (or not on every transcript). Non-deleterious modifications
may have no selective pressure to be removed.
Another major challenge in mRNA cap research is to determine how
many transcribed nucleotides are constituents of the cap. In trypano-
somes and other kinetoplastids, the cap is added to a 39 nucleotide
“splice leader” transcript [110,111]. The process of “trans-splicing”
adds this splice leader to mRNAs, which are transcribed from poly-
cistrons. In this splice leader the first four transcribed nucleotides are
methylated to create the cap 4 structure, m7G(5′)ppp(5′)
m62AmpAmpCmpm3Um [112–114]. Repression of cap methylation in
kinetoplastids results in reduced trans-splicing and translation
[112–115]. Since we now may identify modifications on the 3rd and
4th transcribed nucleotides in mammals, should these all be considered
as part of the cap structure? We propose that the cap structure should
be described on a functional basis, and therefore the question will be-
come, which transcribed nucleotides influence interaction with the
different cap binding complexes? Of note, the cap binding complex,
CBC, is a two subunit, 100 kDa complex in mammals whereas it is a 5
subunit, 300 kDa complex in trypanosomes which may utilise addi-
tional contacts with the extended cap 4 structure [116].
Here we have described how mRNA cap modifications are synthe-
sised, how the activity of the enzymes involved is regulated and how
they influence mRNA processing and gene expression. Future studies
will likely identify novel cap structure, characterise the regulation of
cap formation in vivo and uncover the role of cap diversity in the control
of mammalian cell behaviour.
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